Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors

18 Jul 2022

Abstract excerpt

Targeting glutamine metabolism has emerged as a novel therapeutic strategy for several human cancers, including ovarian cancer. The primary target of this approach is the kidney isoform of glutaminase, glutaminase 1 (GLS1), a key enzyme in glutamine metabolism that is overexpressed in several human cancers. A first-in-class inhibitor of GLS1, called CB839 (Telaglenastat), has been investigated in several clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Neuroendocrine Tumor Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36082022
DOI: 10.1158/2767-9764.crc-22-0122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated TumorsPMID 36082022Read ↗

GLS1 is a protective factor rather than a molecular target in ARID1A-mutated ovarian clear cell carcinomaSemantic proximity Read ↗

Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer.Semantic proximity Read ↗

Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.Semantic proximity Read ↗

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.Semantic proximity Read ↗

The Glutaminase Inhibitor Compound 968 Exhibits Potent in vitro and in vivo anti-tumor Effects in Endometrial CancerSemantic proximity Read ↗

Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the OvariesSemantic proximity Read ↗

Potential therapeutic targets in ARID1A-mutated cancers.Semantic proximity Read ↗

Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the OvariesSemantic proximity Read ↗

In-vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinomaSemantic proximity Read ↗

HIF1α Suppresses Tumor Cell Proliferation through Inhibition of Aspartate BiosynthesisSemantic proximity Read ↗

Functional characterisation of driver events in ovarian clear cell carcinomaSemantic proximity Read ↗

TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.